RAFAEL  A. TORRES, M.D.

 BOARD CERTIFICATION 

 1) Diplomate in the Specialty of Psychiatry.  American Board of  Psychiatry and Neurology. October 1999

 2) Board Certified in the Subspecialty of Psychosomatic Medicine.  American Board of  Psychiatry and Neurology. June 2005

EDUCATION AND TRAINING

 1) Post Graduate Training:     Columbia University College of Physicians and Surgeons.  Residency  in  Psychiatry at  Saint Luke’s - Roosevelt Hospital Center. New York,  New York. July 1994 to June 1998.

 2) Doctor of Medicine:     University of the Philippines College of Medicine. Manila, Philippines.  June 1987 to April 1992

 3) Undergraduate:     Bachelor of Science in Psychology. University of the Philippines. June 1983 to March 1987

PROFESSIONAL  EXPERIENCE

 1)  Attending Psychiatrist.  Butler Hospital. Providence, Rhode Island, 9/2007 to present.

 2)  Medical Associate.  Oaklawn Psychiatric Associates. Cranston, Rhode Island,  8/2009 to present

 3)  Medical Director. Halo Psychiatric Clinic. Cranston, Rhode Island. 1/2006 to 7/2009.

 4) Unit Chief. Geriatric Psychiatry Unit. Our Lady of Fatima Hospital.Joseph Health Services. North Providence, Rhode Island. 3/2005 to 7/2007.

 5) Medical Director. Mental Health Consultation Liaison and Intake Service. Mental Health Product Line. G.V. Montgomery Veterans Affairs Medical Center. Jackson, Mississippi. 9/2003 to 2/2005.

 6) Associate Chief of Staff for Mental Health. G.V. Montgomery Veterans Affairs Medical Center. Jackson, Mississippi. 12/2002 to 9/2003.

 7) Co-Chairman of the Mental Illness Research Education Clinical Center (MIRECC).  Mental Health Service. G.V. Montgomery Veterans Affairs Medical Center.Jackson, Mississippi. 12/2002 to 9/2003.

 8) Co-Team Leader. Schizophrenia Group. South Central Mental Illness Research, Education and Clinical Center  (MIRECC). 4/2002 to 9/2003.

 9) Medical Director. Mental Health Outpatient Service. Mental Health Product Line. G.V. Montgomery Veterans Affairs Medical Center. Jackson, Mississippi . 7/2000 to 11/2002.

 10) Associate Medical Director. Mental Health Consultation and Liaison Service. Mental Health Product Line. G.V. Montgomery Veterans Affairs Medical Center. Jackson, Mississippi. 7/1998 to 7/2000

AWARDS AND HONORS

 1) Teacher of the Year.  University of Mississippi School of Medicine.  Department of Psychiatry and Human Behavior.  Awarded June 2004.

 2) Teacher of the Year.  University of Mississippi School of Medicine.  Department of Psychiatry and Human Behavior.  Awarded June 2002.

 3) Staff Physician of the Year.  G.V. Montgomery Veterans’ Affairs Medical Center.Awarded March 2000.

 4) Physician’s Recognition Award.  American Medical Association. Awarded July 2002.

 5) Physician’s Recognition Award.  American Medical Association. Awarded July 1998.

 6) University of Mississippi Representative. Third Annual Future Leaders in Psychiatry Conference. April 19-22,2001. Boca Raton, FL.

 7) Listed in “Guide to America’s Top Psychiatrists” 2002-2003 Edition. Consumers’ Research Council of America. Washington, DC  2002.

 8) Listed in “Strathmore’s Who’s Who: Medicine and Health Care” 2002-2003 Edition.

 9) Resident Representative. Directory of Psychiatry Residency Training Programs: American Psychiatric Association, American Medical Student Association, Student National Medical Association. 7/1994–98.

 10) Bipolar Disorder Junior Fellow: An Intensive Educational Experience for Psychiatric Residents. New York University School of Medicine. 1997.

CLINICAL RESEARCH

 1) Investigator: Telemedicine Enhanced Antidepressant Management Study (TEAM). Mental Illness Research and Clinical Center (MIRECC). 2003

 2) Principal Investigator:  Prospective, Multi-center, Open-Label Study of Aripiprazole in the Management of Patients with Schizophrenia or Schizoaffective Disorder in General Psychiatric Practices. Broad Effectiveness Trial with Aripiprazole. Bristol-Myers Squibb and Otsuka Maryland Research Institute. 2002.

 3) NIH- RO1 Principal Investigator - University of Mississippi Site: Schizophrenia Liability Genes among African Americans (Project Among African-Americans to Explore Risks for Schizophrenia). National Institute of Health (NIH). 2002.

 4) NIH- RO1 Principal Investigator - University of Mississippi Site: Clinical Antipsychotic Trials of Intervention Effectiveness. A Research Program Studying Treatment Effectiveness and Outcome in Schizophrenia and Alzheimer’s Disease (CATIE). National Institute of Health (NIH). 2001.

 5) Co-Investigator (PI: Dr. H. Nasrallah): A Multicenter, Double blind, Randomized Comparison of the Efficacy and Safety of Sustained-release Formulation Quetiapine Fumarate and Placebo in the Treatment of Patients with Schizophrenia. AstraZeneca. 2001.

 6) Co-Investigator (PI: Dr. D. Mittal): Neuroleptic Treatment of Delirium: A Double Blind Comparison of Risperidone and Haloperidol. 2001.

 7) Co-Investigator (PI: Dr. H. Nasrallah): The Effects of Quetiapine on Tardive Dyskinesia. 2001.

 8) Principal Investigator: Etiological and Phenomenological Assessment of Delirium. 2001.

 9) Co-Investigator (PI: Dr. P. Trzepacz): Validation of the Revised Delirium Rating Scale (DRS). University of Mississippi. 2001

 10) Co-Investigator (PI: Dr. H. Nasrallah): RIS-USA-121 Study: Risperidone depot  (micro spheres) vs. placebo in the treatment of subjects with schizophrenia and schizoaffective disorder. Janssen. 1999 – 2000.

 11) Co-Investigator (PI: Dr. H. Nasrallah):  RIS-USA-196 Study: Risperidone depot open label extension trial. Janssen.  2000.

 12) Co-Investigator (PI: Dr. H. Nasrallah):  ILP3004 Study: A randomized, double blind, placebo- and risperidone-controlled, multi-center study to evaluate the efficacy and safety of two non-overlapping dose ranges of iloperidone to schizophrenic patients with acute or subacute exacerbation, followed by a risperidone-controlled, long term treatment phase with iloperidone given q.d. Novartis. 1999 – 2000.

 13) Co-Investigator (PI: Dr. R. Kennedy): Utility of Routine Anticonvulsant Drug Monitoring Among Psychiatric Patients. 2000.

PUBLICATIONS IN PEER REVIEWED JOURNALS

 1) Reeves R, Torres R: Exacerbation of Psychosis by Misinterpretation of Physical Symptoms. Neuropathic Pain Review Journal. 2005.

 2) Reeves RR, Torres R: Informing Emergency Department patients of the initiation of a psychiatric 72 hour hold. American Journal of Emergency Medicine. 2005.

 3) Mittal D, Torres R, Nasrallah H, et al. Risperidone in the Treatment of Delirium: Results from a Prospective Open-Label Trial. J. Clin. Psychiatry 2004; 65 (5) 662-667.

 4) Reeves R, Torres R: Orally Disintegrating Olanzapine for the Treatment of Psychotic and Behavioral Disturbances Associated with Dementia. Southern Medical Journal 2003; 96 (7) 699 -701.

 5) Reeves R, Torres R: Exacerbation of Psychosis by Misinterpretation of Physical Symptoms. Southern Medical Journal 2003; 96 (7) 702 -703.

 6) Reeves R, Torres R: Medical Disorders Among Psychiatric Patients. Psychiatric Services 2003; 54 (5): 748.

 7) Reeves R, Torres R, Liberto V, Hart R: Atypical Neuroleptic Malignant Syndrome Associated with Olanzapine. Pharmacotherapy  2002;22 (5):641-644.

 8) Torres R, Mittal D, Kennedy R: Use of Quetiapine in Delirium- Case Reports. Psychosomatics. July-August 2001; 42:347-349.

 9) Kennedy R, Mittal D, Torres R, O’Jile J: Electroconvulsive Therapy in Movement Disorders: An Update. The Journal of ECT. 17 (1): 81, 2001.

 10) Reeves R, Torres R, Mack J: Neuroleptic Malignant Syndrome in a Patient being switched from Haloperidol to Risperidone. The Annals of Pharmacotherapy 2001; 35 (6): 698-701.

 11) Trzepacz PT, Mittal D, Torres R, Kanary K, Norton J, Jimerson N: Validation of the Delirium Rating Scale-revised-98: Comparison to the Delirium Rating Scale and Cognitive Test for Delirium. The Journal of Neuropsychiatry and Clinical Neurosciences. Spring 2001; 13 (2): 229-42.

 12) Mittal D, Torres R, Abashidzi A, Jimerson N: Worsening of Posttraumatic Stress Disorder Symptoms with Cognitive Decline: A Case Series. Journal of Geriatric Psychiatry and Neurology 2001; 14:17-20.

 13) Lam C, Torres R, Godding P, Mittal D: The Relationship Between Cognitive Dysfunction and Depressive Symptoms in an Outpatient Psychiatric Population. Journal of the Mississippi Academy of Sciences. February 2000.

 14) Trzepacz PT, Mittal D. Torres R: Delirium Phenomenology Using the Delirium Rating Scale-Revised-98 (DRS-R-98).

PUBLISHED  ABSTRACTS 

 1) Predictors of Reversibility of Olanzapine-Induced Diabetes Mellitus. Torres R, Nasrallah H, Perry CL, Love E. Presented at the 156th American Psychiatric Association Annual Meeting. San Francisco, California. May 17 - 22, 2003.

 2) Diabetes Mellitus Associated with Olanzapine Treatment: Incidence, Risk Factors and Reversibility. Torres R, Nasrallah H, Perry C, Love E. Presented at the Academy of Psychosomatic Medicine Annual Meeting. Tucson, Arizona. November 21 – 24, 2002.

 3) Diabetes and Body Mass Index in Patients with Bipolar Disorder Receiving Various Atypical Antipsychotics. Torres R, Nasrallah H, Perry C, Love E. Presented at the 54th Institute on Psychiatric Services Annual Meeting. Chicago, Illinois. October 9 –13, 2002.

 4) Successful Treatment of Delirium with Risperidone. Mittal, D; Nasrallah, H; Torres, R. Presented at The American Geriatric Society Annual Meeting. Washington, D.C. May 8 –14, 2002.

 5) Successful Treatment of Delirium with Risperidone: A Case Study. Mittal, D; Nasrallah, H; Torres, R. Presented at the International College of Geriatric Psychoneuropharmacology. Waikoloa, Hawaii. December 14 – 15, 2001.

 6) Delirium vs. Dementia Symptoms: Delirium Rating Scale-Revised-98 (DRS-98) and Cognitive Test for Delirium (CTD) Item Comparisons.  Trzepacz, PT; Mittal, D; Torres, R. Presented at the Academy of Psychosomatic Medicine 48th Annual Meeting. San Antonio, Texas. November 15 – 18, 2001.

 7) The Relationship between Cognitive Dysfunction and Depressive Symptoms in an Outpatient Psychiatric Population. Lam C, Torres R, Godding P. Presented at the Mississippi Academy of Sciences Annual Meeting. Biloxi, Mississippi. February 2000.

 8) Validation of the Delirium Rating Scale-revised-98: Comparison to the Delirium Rating Scale and Cognitive Test for Delirium. Trzepacz PT, Mittal D, Torres R. Presented at the Academy of Psychosomatic Medicine 46th Annual Meeting. New Orleans, Louisiana. November 1999.

 PRESENTATIONS

 1) “Management of Behavioral and Cognitive Disturbances in Dementia.” Nursing Service Seminar. Geriatric Workshop. Jackson, Mississippi. August 20, 2003.

 2) Postpartum Depression and Psychosis: Is there an Andrea Yates in your practice?” National Association of Social Workers. Jackson, Mississippi. December 17, 2002.

 3) The Clinical Antipsychotic Trials of Intervention Effectiveness: Bridging the Efficacy-Effectiveness Gap.” University of Arkansas Medical School Department of Psychiatry Grand Rounds. August 8, 2002.

 4) Closing the  Efficacy – Effectiveness Gap through Clinical Research.” VA South Central Mental Illness Research, Education and Clinical Center  (MIRECC) Annual Conference. Jackson, Mississippi. April 25, 2002.

 5) Ziprasidone in the Management of Schizophrenia and Schizoaffective Disorder in the Jackson VAMC Outpatient Clinic Population.” New Orleans VA Medical Center. April 23, 2002.

 6) Are Delirium and Dementia Different?”  Trzepacz, PT; Mittal, D; Torres, R. Presented at the American Neuropsychiatric Association Third Annual Meeting. La Jolla, California. March 9 – 12, 2002.

 7) Successful Treatment of Delirium with Risperidone.” Mittal, D; Nasrallah, H; Torres, R. Presented at The American Association for Geriatric Psychiatry Annual Meeting. Orlando, Florida. February 24 – 27, 2002

PROFESSIONAL  AFFILIATIONS

 1) American Psychiatric Association.  Member.  1995 to present.

 2) American Medical Association.  Member.  1995 to present.

 3) Academy of Psychosomatic Medicine.  Member. 1999 to present.

 4) American Academy of Clinical Psychiatrists.  Member.  2001 to present.

 5) Charles F. Menninger Society. Menninger Foundation.  Member. 1997 to present.

 6) National Alliance for the Mentally Ill.  Professional Associate Member. 1997 to present.

 7) Physician Leadership on National Drug Policy.  Physician Associate. 1998 to present.